NCT03801759COMPLETEDanonymous

A Phase 1 Open-label, Three Arm Study in Healthy Adult Volunteers to Assess Vadadustat as a Perpetrator in Drug-Drug-Interactions With Digoxin, Adefovir and Furosemide

Sponsor

Source record

Akebia Therapeutics

Phase

Source record

Phase 1

Modality

AI-normalized

small molecule

Target

AI-normalized

Vadadustat

Indication / condition

AI-normalized

Drug Interaction Potentiation

Intervention

Source record

Vadadustat, Furosemide, Adefovir, Digoxin

Related intelligence directories

Indication directory: Drug Interaction Potentiation Modality directory: small molecule Target directory: Vadadustat

Source & freshness

Source record

NCT ID

NCT03801759

Original source

ClinicalTrials.gov

Source last updated

Mar 22, 2019

Ingested at

Jun 03, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT03801759

Title

A Phase 1 Open-label, Three Arm Study in Healthy Adult Volunteers to Assess Vadadustat as a Perpetrator in Drug-Drug-Interactions With Digoxin, Adefovir and Furosemide

Sponsor

Akebia Therapeutics

Status

COMPLETED

Phase

Phase 1

Condition raw

Drug Interaction Potentiation

Condition normalized

Drug Interaction Potentiation

Modality raw

Drug Interaction Potentiation

Modality normalized

small molecule

Target raw

Vadadustat

Target normalized

Vadadustat

Interventions

Vadadustat, Furosemide, Adefovir, Digoxin

Public preview

Source record

Akebia Therapeutics conducted a Phase 1 open-label study to evaluate the potential drug-drug interactions of Vadadustat with Digoxin, Adefovir, and Furosemide in healthy volunteers. The study aimed to assess pharmacokinetics and safety profiles.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase 1 Open-label, Three Arm Study in Healthy Adult Volunteers to Assess Vadadustat as a Perpetrator in Drug-Drug-Interactions With Digoxin, Adefovir and Furosemide

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 20, 2026

NCT ID

NCT03801759

Status

COMPLETED

Phase

Phase 1

Sponsor

Akebia Therapeutics

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedMar 22, 2019

Internal syncJun 05, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT03801759

Indication

Drug Interaction Potentiation

Modality

small molecule

Target

Vadadustat

Intervention

Vadadustat, Furosemide, Adefovir, Digoxin

Source record